Check-Cap (NASDAQ:CHEK) Share Price Crosses Above 50-Day Moving Average of $3.08

Check-Cap Ltd. (NASDAQ:CHEK)’s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $3.08 and traded as high as $3.61. Check-Cap shares last traded at $3.50, with a volume of 5,085 shares traded.

Analyst Upgrades and Downgrades

CHEK has been the subject of several analyst reports. HC Wainwright lowered shares of Check-Cap from a “buy” rating to a “neutral” rating in a research note on Wednesday, June 7th. StockNews.com initiated coverage on Check-Cap in a research report on Thursday, August 17th. They set a “hold” rating for the company.

Check-Cap Trading Up 0.3 %

The company has a market capitalization of $16.97 million, a PE ratio of -1.34 and a beta of 0.77. The stock’s fifty day moving average is $3.08 and its two-hundred day moving average is $2.39.

Check-Cap (NASDAQ:CHEK) last released its earnings results on Friday, August 4th. The medical research company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.50). As a group, analysts anticipate that Check-Cap Ltd. will post -1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Check-Cap

Several institutional investors and hedge funds have recently bought and sold shares of CHEK. Sabby Management LLC purchased a new position in shares of Check-Cap during the 1st quarter valued at $91,000. Virtu Financial LLC raised its stake in Check-Cap by 363.4% in the 2nd quarter. Virtu Financial LLC now owns 224,696 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 176,207 shares during the period. Susquehanna International Group LLP purchased a new stake in Check-Cap during the first quarter valued at about $57,000. Finally, Citadel Advisors LLC boosted its position in Check-Cap by 51.2% during the third quarter. Citadel Advisors LLC now owns 141,319 shares of the medical research company’s stock worth $41,000 after purchasing an additional 47,868 shares during the period. 0.21% of the stock is owned by institutional investors.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.